MedTrace Logo

MSD Belzutifan PAS

NCT06554730 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-11-29

No results posted yet for this study

Summary

This is a prospective observational cohort study evaluating the effectiveness and safety of belzutifan treatment in routine clinical practice.

This study has been registered and will be maintained through close out on the RWD Catalogues Observational Registry - https://catalogues.ema.europa.eu/ under the EU PAS number:

EUPAS108114

Conditions

  • Von Hippel Lindau Disease

Interventions

OTHER

Belzutifan

There is no intervention for this study. This study will be collecting data from the EMR of consenting subjects who are taking Belzutifan.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2030-12-31
Completion
2030-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06554730 on ClinicalTrials.gov